Compared to statin users, PCSK9 inhibitor users had significantly lower risks of AMD (HR, 0.81; 95% confidence interval [CI], 0.72-0.92) and dry AMD (HR, 0.78; 95% CI, 0.65-0.94), but not wet AMD (HR, 0.90; 95% CI, 0.70-1.16). Here, PCSK9 is linked to dry age related macular degeneration.